New hope for recurrent liver cancer after transplant?
NCT ID NCT05103904
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tested the drug lenvatinib in people whose liver cancer returned after a liver transplant. The goal was to see if the drug could shrink or slow the cancer. Only 3 people took part before the study was stopped early. The drug works by blocking enzymes that help cancer cells grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Mayo Clinic Arizona
Scottsdale, Arizona, 85259, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.